Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock linked to the Offering Documents from the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will receive updates through a portfolio monitoring software [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [6].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100 [1][2]. Group 1: Allegations and Class Period - The lawsuit claims that during the class period, the defendants made materially false and misleading statements about ALTO-100's effectiveness in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [2]. - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1][2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiffs and to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug ALTO-100, which failed to meet primary endpoints in clinical trials, leading to significant stock price decline [3][4][5]. Group 1: Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company focused on developing treatments for major depressive disorder (MDD) [3]. - The company conducted its initial public offering (IPO) on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Group 2: Allegations and Impact - The lawsuit claims that during the Class Period, Alto Neuroscience made false or misleading statements about the effectiveness of ALTO-100, overstating its clinical and commercial prospects [4]. - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - As of the filing of the class action, Alto Neuroscience's stock continues to trade below the IPO price of $16.00 per share [6].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the effectiveness of Alto's product pipeline, specifically ALTO-100, in treating major depressive disorder was overstated [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were misrepresented, leading to an inflated perception of Alto's business and financial outlook [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [6].

Core Points - A lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) for alleged violations of securities laws related to its IPO and subsequent statements [3] - Investors who purchased over $100,000 in shares between February 2, 2024, and October 22, 2024, have a deadline of September 19, 2025, to take action [2] - The lawsuit claims that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated, leading to misleading public statements about the company's financial and business prospects [3] Company Information - Alto Neuroscience, Inc. is facing legal scrutiny due to allegations that its IPO documents contained false or misleading information regarding its product's effectiveness [3] - The Shareholders Foundation, Inc. is facilitating communication for affected investors and provides services related to shareholder issues and securities class actions [4]